Clinical Trials Browser

Interventional × Squamous Cell Carcinoma of Head and Neck × Dasatinib × Clear all

NCT05724329 2024-09-19

Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT00882583 2019-01-09

Dasatinib

Phase 1 Terminated

22 enrolled 8 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT01488318 2018-01-05

Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma

Phase 2 Terminated

21 enrolled 8 charts

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT00507767 2014-10-01

Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Phase 2 Completed

15 enrolled 8 charts

Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms